CDDD2-94
Modify Date: 2024-09-21 19:37:09
CDDD2-94 structure
|
Common Name | CDDD2-94 | ||
|---|---|---|---|---|
| CAS Number | 2078047-99-9 | Molecular Weight | 442.561 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H27FN8S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CDDD2-94CDDD2-94 is a highly potent and selective CDK4 inhibitor with Ki of 2 nM, >140-fold selective for CDK4 over CDK6 (Ki=279 nM).CDDD2-94 is ineffective against other members of the CDK family, displays high selectivity against a panel of 369 human kinases at 1uM, with exceptionally selective-CLK, DYRKs and MYLK4 were the only kinases targeted potently.CDDD2-94 is the most selective CDK4 inhibitor identified to date.CDDD2-94 demonstrated antiproliferative activityagainst MV4-11 and MDA-MB-453 cell lines with GI50 of 0.107 and 0.325 uM respectively.CDDD2-94 inhibits S780-phosphorylated Rb (pRb(S780)) and decreases transcription of Rb1 and E2F-target genes in MDA-MB-453 cells.CDDD2-94 is well tolerated and efficacious in preclinical OC xenograft model, CDDD2-94 provides better safety profile than palbociclib towards the bone marrow. |
| Name | CDDD2-94 |
|---|
| Description | CDDD2-94 is a highly potent and selective CDK4 inhibitor with Ki of 2 nM, >140-fold selective for CDK4 over CDK6 (Ki=279 nM).CDDD2-94 is ineffective against other members of the CDK family, displays high selectivity against a panel of 369 human kinases at 1uM, with exceptionally selective-CLK, DYRKs and MYLK4 were the only kinases targeted potently.CDDD2-94 is the most selective CDK4 inhibitor identified to date.CDDD2-94 demonstrated antiproliferative activityagainst MV4-11 and MDA-MB-453 cell lines with GI50 of 0.107 and 0.325 uM respectively.CDDD2-94 inhibits S780-phosphorylated Rb (pRb(S780)) and decreases transcription of Rb1 and E2F-target genes in MDA-MB-453 cells.CDDD2-94 is well tolerated and efficacious in preclinical OC xenograft model, CDDD2-94 provides better safety profile than palbociclib towards the bone marrow. |
|---|---|
| References | 1. Laychiluh Bantie, et al. Gynecol Oncol. 2020 Dec;159(3):827-838. 2. Solomon Tadesse, et al. Br J Pharmacol. 2018 Jun;175(12):2399-2413. |
| Molecular Formula | C21H27FN8S |
|---|---|
| Molecular Weight | 442.561 |